PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms

The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.